These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 34814904

  • 1. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 2. Inhibiting MAPK14 showed anti-prolactinoma effect.
    Ding QY, Zhang Y, Ma L, Chen YG, Wu JH, Zhang HF, Wang X.
    BMC Endocr Disord; 2020 Sep 07; 20(1):138. PubMed ID: 32894113
    [Abstract] [Full Text] [Related]

  • 3. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
    Tang C, Zhu J, Yuan F, Yang J, Cai X, Ma C.
    Mol Neurobiol; 2021 Dec 07; 58(12):6170-6185. PubMed ID: 34463926
    [Abstract] [Full Text] [Related]

  • 4. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
    Li Z, Liu Q, Li C, Zong X, Bai J, Wu Y, Lan X, Yu G, Zhang Y.
    Mol Cell Endocrinol; 2015 Feb 15; 402():64-71. PubMed ID: 25578603
    [Abstract] [Full Text] [Related]

  • 5. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
    Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E.
    Biol Reprod; 2000 Jun 15; 62(6):1486-94. PubMed ID: 10819748
    [Abstract] [Full Text] [Related]

  • 6. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
    Li Q, Su Z, Liu J, Cai L, Lu J, Lin S, Xiong Z, Li W, Zheng W, Wu J, Zhuge Q, Wu Z.
    Mol Cell Endocrinol; 2014 Jan 25; 382(1):377-384. PubMed ID: 24184771
    [Abstract] [Full Text] [Related]

  • 7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
    Cai L, Leng ZG, Guo YH, Lin SJ, Wu ZR, Su ZP, Lu JL, Wei LF, Zhuge QC, Jin K, Wu ZB.
    Endocrine; 2016 Jun 25; 52(3):641-51. PubMed ID: 26662185
    [Abstract] [Full Text] [Related]

  • 8. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H, Zhu Y.
    J Endocrinol Invest; 2019 Jun 25; 42(6):639-652. PubMed ID: 30370446
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Gao H, Wang F, Lan X, Li C, Feng J, Bai J, Cao L, Gui S, Hong L, Zhang Y.
    BMC Cancer; 2015 Apr 12; 15():272. PubMed ID: 25884948
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J.
    Acta Neurochir (Wien); 2005 Jul 12; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [Abstract] [Full Text] [Related]

  • 13. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
    Wang F, Gao H, Li C, Bai J, Lu R, Cao L, Wu Y, Hong L, Wu Y, Lan X, Zhang Y.
    J Neurooncol; 2014 Jan 12; 116(1):83-8. PubMed ID: 24135847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Zhu J, Tang C, Cong Z, Yuan F, Cai X, Yang J, Ma C.
    Endocr Relat Cancer; 2021 Dec 13; 29(2):33-46. PubMed ID: 34821219
    [Abstract] [Full Text] [Related]

  • 16. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
    Zhu K, Cheng X, Wang S, Zhang H, Zhang Y, Wang X, Chen Y, Wu J.
    Front Endocrinol (Lausanne); 2021 Dec 13; 12():706909. PubMed ID: 35126305
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.